iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
83 hedge funds and large institutions have $754M invested in iTeos Therapeutics in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 20 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2% more funds holding
Funds holding: 81 → 83 (+2)
1.77% less ownership
Funds ownership: 85.72% → 83.95% (-1.8%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
27% less capital invested
Capital invested by funds: $1.03B → $754M (-$274M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.5M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.5M |
| 4 |
Citigroup
New York
|
+$9.46M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.6M |
| 2 |
RI
RTW Investments
New York
|
-$24.9M |
| 3 |
CAC
Cowen and Company
New York
|
-$20.1M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$11M |
| 5 |
State Street
Boston,
Massachusetts
|
-$9.17M |
ITOS Hedge Fund Activity: Q2 2021 in Review
83 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q2 2021, worth a combined $754M — down 27% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ITOS positions and 20 closed out — a net gain of 2 holders — while 30 added to existing stakes and 23 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $18.5M. The largest seller was Adage Capital Partners, cutting an estimated $28.6M.
- 83 institutional investors held iTeos Therapeutics (ITOS) as of Q2 2021, up from 81 in Q1 2021.
- Funds reported $754M of iTeos Therapeutics stock for Q2 2021, down 27% quarter-over-quarter.
- 22 funds opened new iTeos Therapeutics positions in Q2 2021 and 20 closed out, a net change of +2 holders.
- The largest iTeos Therapeutics buyer in Q2 2021 was EcoR1 Capital, an estimated $18.5M added.
- The largest iTeos Therapeutics seller in Q2 2021 was Adage Capital Partners, an estimated $28.6M sold.
Based on aggregated 13F filings for Q2 2021.